Trial
NCT03755518
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Celgene
Collaborators
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
Condition
Primary Myelofibrosis
Intervention
FEDRATINIB
Why stopped
Slow accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-12